AxoGen, Inc. to Post FY2017 Earnings of ($0.31) Per Share, Cantor Fitzgerald Forecasts (AXGN)
AxoGen, Inc. (NASDAQ:AXGN) – Cantor Fitzgerald issued their FY2017 earnings per share estimates for shares of AxoGen in a research report issued on Sunday. Cantor Fitzgerald analyst C. Bijou forecasts that the medical equipment provider will post earnings per share of ($0.31) for the year. Cantor Fitzgerald currently has a “Buy” rating and a $37.00 target price on the stock. Cantor Fitzgerald also issued estimates for AxoGen’s FY2018 earnings at ($0.27) EPS.
AxoGen (NASDAQ:AXGN) last announced its quarterly earnings results on Wednesday, November 1st. The medical equipment provider reported ($0.06) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.06). AxoGen had a negative net margin of 24.74% and a negative return on equity of 91.00%. The business had revenue of $16.05 million during the quarter, compared to analysts’ expectations of $15.55 million. AxoGen’s quarterly revenue was up 43.2% on a year-over-year basis.
AXGN has been the subject of a number of other reports. Jefferies Group began coverage on shares of AxoGen in a research report on Thursday, November 30th. They set a “buy” rating and a $35.00 price target for the company. BidaskClub lowered shares of AxoGen from a “strong-buy” rating to a “buy” rating in a research note on Thursday. Leerink Swann reissued an “outperform” rating and issued a $23.00 price objective (up previously from $22.00) on shares of AxoGen in a research note on Saturday, September 30th. Wedbush reissued a “buy” rating and issued a $27.00 price objective (up previously from $22.00) on shares of AxoGen in a research note on Tuesday, November 21st. Finally, Lake Street Capital raised their price objective on shares of AxoGen from $22.00 to $26.00 and gave the company a “buy” rating in a research note on Tuesday, November 21st. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $29.33.
Shares of AxoGen (NASDAQ:AXGN) opened at $27.75 on Wednesday. AxoGen has a 12-month low of $8.75 and a 12-month high of $31.70. The firm has a market cap of $930.76, a PE ratio of -66.07 and a beta of 0.89. The company has a debt-to-equity ratio of 1.93, a quick ratio of 2.95 and a current ratio of 3.55.
Large investors have recently modified their holdings of the company. Neuberger Berman Group LLC purchased a new stake in shares of AxoGen during the 2nd quarter worth approximately $201,000. Valeo Financial Advisors LLC purchased a new stake in shares of AxoGen during the 3rd quarter worth approximately $244,000. OxFORD Asset Management LLP purchased a new stake in shares of AxoGen during the 3rd quarter worth approximately $270,000. Nationwide Fund Advisors lifted its position in shares of AxoGen by 5.5% during the 2nd quarter. Nationwide Fund Advisors now owns 14,874 shares of the medical equipment provider’s stock worth $249,000 after buying an additional 774 shares during the last quarter. Finally, Susquehanna International Group LLP lifted its position in shares of AxoGen by 247.1% during the 2nd quarter. Susquehanna International Group LLP now owns 16,619 shares of the medical equipment provider’s stock worth $278,000 after buying an additional 27,919 shares during the last quarter. Institutional investors and hedge funds own 66.00% of the company’s stock.
In other news, Director Guido J. Neels sold 1,150,000 shares of the business’s stock in a transaction that occurred on Monday, November 20th. The shares were sold at an average price of $19.74, for a total transaction of $22,701,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Jamie Mark Grooms sold 38,405 shares of the business’s stock in a transaction that occurred on Tuesday, December 12th. The stock was sold at an average price of $26.35, for a total transaction of $1,011,971.75. The disclosure for this sale can be found here. Insiders sold 1,293,990 shares of company stock valued at $26,494,898 in the last quarter. 9.33% of the stock is owned by insiders.
AxoGen, Inc provides surgical solutions for peripheral nerve injuries. The companys surgical nerve repair solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect injured peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments.
Receive News & Ratings for AxoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen and related companies with MarketBeat.com's FREE daily email newsletter.